Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy

References

• Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168–2179. doi:10.1016/S0140-6736(13)61903-0
   PubMed Web of Science ®Google Scholar
• Braconi C, Patel T. Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am. 2010;24(4):871–84, vii. doi:10.1016/j.idc.2010.07.006
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–1357. doi:10.1053/jhep.2001.25087
   PubMed Web of Science ®Google Scholar
• Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise. Oncologist. 2016;21:594–599. doi:10.1634/theoncologist.2015-0446
   PubMed Web of Science ®Google Scholar
• Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM. Impact of classification of hilarcholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98:873–875. doi:10.1093/jnci/djj234
   PubMedGoogle Scholar
• Adeva J, Sangro B, Salati M, et al. Medical treatment for cholangiocarcinoma. Liver Int. 2019;39:123–142. doi:10.1111/liv.14100
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281. doi:10.1056/NEJMoa0908721
   PubMed Web of Science ®Google Scholar
• Valle J, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. Biliary Cancer: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v28–v37. doi:10.1093/annonc/mdw324
   PubMed Web of Science ®Google Scholar
• Lamarca A, Hubner RA, David Ryder W, Valle J. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;5(12):2328–2338. doi:10.1093/annonc/mdu162
   Web of Science ®Google Scholar
• Salati M, Caputo F, Cunningham D, et al. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. Eur J Cancer. 2019;117:84–90. doi:10.1016/j.ejca.2019.05.030
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Lopes A, Wasan H, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016;27:134–140. doi:10.1093/annonc/mdv483
   PubMed Web of Science ®Google Scholar
• McNamara MG, Templeton AJ, Maganti M, et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50:1581–1589. doi:10.1016/j.ejca.2014.02.015
   PubMed Web of Science ®Google Scholar
• Peixoto RD, Renouf D, Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol. 2014;5:428–432. doi:10.3978/j.issn.2078-6891.2014.081
   PubMedGoogle Scholar
• Suzuki Y, Kan M, Kimura G, et al. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. J Gastroenterol. 2019;54:281–290. doi:10.1007/s00535-018-1518-3
   PubMed Web of Science ®Google Scholar
• Salati M, Caputo F, Cerma K, Marcheselli L, Braconi C, Cascinu S. The impact of gender and immune system determinants on long-term survival in biliary tract cancer. Ital J Gend Specif Med. 2019;5:27–30. doi:10.1723/3148.31296
   Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a Phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690–701. PMCID: PMC8082275. doi:10.1016/S1470-2045(21)00027-9
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. ABC-06: a randomised Phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. Proc Am Soc Clin Oncol. 2019;37:Article 4003.
   Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81. doi:10.1080/01621459.1958.10501452
   Web of Science ®Google Scholar
• Cox D. Regression models and life tables. J R Stat Soc. 1972;34:187–202. Series B.
   Google Scholar
• Schoenfeld D. Partial residuals for proportional hazard regression model. Biometrika. 1982;69:239–41. doi:10.1093/biomet/69.1.239
   Web of Science ®Google Scholar
• Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–344. doi:10.1111/j.0006-341X.2000.00337.x
   PubMed Web of Science ®Google Scholar
• Harrel FE, Lee HL, Mark DB. Multivariable prognostic model: issues in developing model. Evaluating assumptions and adequacy and measuring and reducing errors. Stat Med. 1996;15:361–87.
   PubMed Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36:276–282. doi:10.1200/JCO.2017.75.5009
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Arkenau H, Tran B, et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Ann Oncol. 2018;29:ix46–ix66. doi:10.1093/annonc/mdy149
   Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, Phase 2 study. Lancet Oncol. 2020;21:671–684. doi:10.1016/S1470-2045(20)30109-1
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120:165–171. doi:10.1038/s41416-018-0334-0
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla Mercade T, Javle M, et al. ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann Oncol. 2019;30(mdz394.027.):v872–v873. doi:10.1093/annonc/mdz394.027
   Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796–807. doi:10.1016/S1470-2045(20)30157-1
   PubMed Web of Science ®Google Scholar
• Salati M, Braconi C. Noncoding RNA in Cholangiocarcinoma. Semin Liver Dis. 2019;39:013–025. doi:10.1055/s-0038-1676097
   PubMed Web of Science ®Google Scholar
• Carotenuto P, Hedayat S, Fassan M, et al. Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells. Hepatology. 2019. doi:10.1002/hep.31094
   Web of Science ®Google Scholar
• Salati M, Filippi R, Vivaldi C, et al. The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. Liver Int. 2019. doi:10.1111/liv.14314
   Web of Science ®Google Scholar
• Lowery MA, Goff LW, Keenan BP, et al. Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes. Cancer. 2019;125(24):4426–4434. doi:10.1002/cncr.32463
   PubMed Web of Science ®Google Scholar
• Fornaro L, Cereda S, Aprile G, et al. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014;110:2165–2169. doi:10.1038/bjc.2014.190
   PubMed Web of Science ®Google Scholar
• Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer. 2013;49(2):329–335. doi:10.1016/j.ejca.2012.08.003
   PubMed Web of Science ®Google Scholar
• Brieau B, Dahan L, De Rycke Y, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer. 2015;121(18):3290–3297. doi:10.1002/cncr.29471
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Casadei Gardini A, Brieau B, et al. Prediction of survival with second-line therapy in biliary tract cancer: actualisation of the AGEO CT2BIL cohort and European multicentre validations. Eur J Cancer. 2019;111:94–106. doi:10.1016/j.ejca.2019.01.019
   PubMed Web of Science ®Google Scholar